Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inspira Technologies Oxy BHN ( (IINN) ) just unveiled an update.
Inspira Technologies Oxy B.H.N. Ltd., a commercial-stage Israeli MedTech company specializing in respiratory support systems and blood monitoring technologies, is leveraging its FDA-cleared INSPIRA ART100 and pipeline platforms such as INSPIRA ART500 and HYLA to build a broader life-support technology portfolio. The company has been streamlining operations and expanding its intellectual property base to strengthen its positioning within the global medical device and life-support ecosystem.
On February 19, 2026, Inspira Technologies amended a senior convertible debenture with Bio-View Ltd., extending the deadline for satisfying key prerequisites from 45 to 75 days and shifting a required $5 million fund-raising condition to investments sourced via A.G.P./Alliance Global Partners. The company also disclosed that it received a Nasdaq notice on February 19, 2026, for failing to meet the $35 million minimum market value of publicly held shares requirement, giving it until August 18, 2026, to regain compliance or risk potential delisting proceedings, a development that heightens regulatory and market pressure on management and shareholders.
The most recent analyst rating on (IINN) stock is a Sell with a $0.68 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.
The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies OXY B.H.N. Ltd. is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., while the INSPIRA ART500 and HYLA blood-sensor platform aim to expand its footprint in life-support and MedTech markets.
Average Trading Volume: 601,794
Technical Sentiment Signal: Sell
Current Market Cap: $25.36M
See more data about IINN stock on TipRanks’ Stock Analysis page.